Clay Siegall is the founder and chief executive officer of Seattle Genetics. The Seattle-based biotech company engages in the development of targeted therapy drugs. The corporation zeroes in on the diseases that have not seen considerable mortality improvements for several years. Dr. Siegall holds a B.S. degree in zoology from the prestigious University of Maryland. He also holds a PhD in genetics from the renowned George Washington University.
Since 1998 when the Seattle Genetics was incorporated, Siegall has provided visionary leadership that has helped the company to maintain its authority in the competitive targeted therapy sector. The company developed the first FDA-approved antibody drug conjugate. Moreover, the corporation has a robust pipeline of over 20 drugs and a number of strategic partnerships with Genentech, Bayer, Pfizer and many other drug manufacturers.
Under Siegall’s leadership, Seattle Genetics evolved from a tiny startup with few researchers to a power house in the cancer research industry. Siegall has grand plans for the firm’s future, including the development of different prospective indications and growing list of drugs. Notably, the success of the company is anchored on its research capabilities. Siegall believes that conventional cancer treatment approaches such as systematic chemotherapies will have no place in the future. This is because targeted therapies are more effective and tolerable.
Speaking on how he started in the business, Siegall said that he was always interested in medicine and the power of technology in restoring the health of people. The executive contends that he developed a deep interest in cancer treatment while he was studying zoology at the university.
About Clay Siegall
Clay Siegall is the chairman of the board at Seattle Genetics. The visionary leader has vast experience in developing viable targeted cancer therapies. He has built Seattle Genetics on a strong foundation of drug development practices, rigorous research, scientific innovation, and passion for helping patients.
Siegall has also led the capital raising activities of Seattle Genetics. He has secured more than $675 million for the company through various methods of financing. Before forming the biotech firm, Siegall worked for the National Cancer Institute and the Bristol-Myers Squibb Pharmaceutical Research Institute. Clay has authored more than 70 publications.